Olmesartan Medoxomil Actavis (Olmesartan Medoxomil)

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.
• Heart failure: used as part of combination therapy to improve symptoms and outcomes.

• Olmesartan medoxil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding to this receptor, it inhibits vasoconstriction, aldosterone secretion, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure.

Adverse reactions to olmesartan medoxil are generally mild to moderate and vary with individual tolerance.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhoea
• Cough

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevations
• Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing olmesartan medoxil, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure adequate control without excessive lowering.
• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium levels, especially with concomitant potassium‑sparing agents.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Drug interactions: review concomitant antihypertensives and NSAIDs for additive effects.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil may interact with several medicines that affect blood pressure, renal function, or potassium balance.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetic patients increases risk of renal impairment and hyperkalaemia.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia.
• ACE inhibitors: concurrent use can lead to additive hypotensive effects and renal dysfunction.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function.
• Lithium: ARBs can increase lithium levels, risking toxicity.
• Diuretics (thiazides): may enhance hypotensive effect and alter electrolytes.